stock-PR.com's  Instablog

FREE Daily Stock Alerts From Stock-PR.com

ACAD, ACADIA Pharmaceuticals Inc.

** ACAD reported successful top-line results from its pivotal Phase III trial evaluating the efficacy, tolerability and safety of pimavanserin in patients with Parkinson’s disease psychosis (PDP).

Pimavanserin is ACAD’s proprietary, non-dopaminergic product candidate that selectively blocks serotonin 5-HT2A receptors.

Pimavanserin met the primary endpoint in the Phase III trial by demonstrating highly significant antipsychotic efficacy as measured using the 9-item SAPS-PD scale (p=0.001). Pimavanserin also met the key secondary endpoint for motoric tolerability as measured using Parts II and III of the Unified Parkinson’s Disease Rating Scale, or UPDRS. These results were further supported by a highly significant improvement in the secondary efficacy measure, the Clinical Global Impression Improvement, or CGI-I, scale (p=0.001).

In addition, clinical benefits were observed in all exploratory efficacy measures with significant improvements in nighttime sleep, daytime wakefulness and caregiver burden. Consistent with previous studies, pimavanserin was safe and well tolerated in this Phase III trial.

According to the National Parkinson’s Foundation, about one million people in the United States and from four to six million people worldwide suffer from Parkinson’s disease. Parkinson’s disease psychosis, or PDP, is a debilitating disorder that develops in up to 60 percent of patients with Parkinson’s disease.

ACAD is a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders.

More about ACAD at www.acadia-pharm.com

**************************************************************

Read Full Disclaimer at http://stock-pr.com/disclaimer

stock-pr.com/22048/stock-alerts/acadia-p.../

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

FREE Daily Stock Alerts From Stock-PR.com

GALT, Galectin Therapeutics, Inc.

** GALT reported that it has received a notice of allowance from the U.S. Patent and Trademark Office for a divisional patent of Patent Number 8,236,780 “Galactose-prolonged polysaccharides in a formulation for antifibrotic therapies”.

The patent covers key methods of derivation and use for the Company’s galactomannan-based carbohydrate galectin inhibitor compounds, for use in patients with chronic liver disease associated with the development of fibrosis, established liver fibrosis or end-stage scarring, or cirrhosis.

Fibrotic disease of the liver is highly prevalent in the population because all chronic liver diseases, including viral hepatitis, fatty liver and alcohol abuse, result in fibrosis of the liver for which there are no currently approved pharmaceutical therapies.

GALT is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function.

More about GALT at www.galectintherapeutics.com.

**************************************************************

Read Full Disclaimer at http://stock-pr.com/disclaimer

stock-pr.com/22047/stock-alerts/galectin.../

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

FREE Daily Stock Alerts From Stock-PR.com

VOLC, Volcano Corporation

** VOLC reported that it has entered into a definitive agreement to acquire Sync-Rx Ltd., a privately-held company based in Israel that develops advanced software applications that optimize and facilitate transcatheter cardiovascular interventions using automated online image processing. It is anticipated the transaction will close within the next 30 days.

Sync-Rx's technology will allow VOLC to better integrate and present a wide variety of data in an intuitive manner that creates more meaningful information for the physician and documentation for the hospital.

VOLC is revolutionizing the medical device industry with a broad suite of technologies that make imaging and therapy simpler, more informative and less invasive.

More about VOLC at www.volcanocorp.com.

**************************************************************

Read Full Disclaimer at http://stock-pr.com/disclaimer

stock-pr.com/22042/stock-alerts/volcano-.../

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.